CLDI

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

SCHEDULE 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

10-Q - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the versatility of its RedTail platform at the 2026 ASCO Annual Meeting with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifier; the Company is also advancing its EpCam-targeted in situ TCE program, representing an important advancement of the RedTail platform Strengthened its Board of Directors with the addition of Corsee Sanders, Ph.D., former executive of Genentech/Roche and Celgene Re

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter of 2027 and its in situ T-cell engager (TCE) program. "The data presented last week at the conference shows the advances we have made in both our CLD-401 program that we expect will be entering the clinic so

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027  Company demonstrated the versatility of the RedTail platform with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifiers. The Company is also advancing its EpCam-targeted In Situ TCE program. In Situ TCEs represent an important advancement of the RedTail platform Strengthened Board of Directors with addition of Corsee Sanders, Ph.D., former executive of Genentech/Roche and CelgeneComp

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the "Reverse Stock Split"). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 under the existing symbol of "CLDI." The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 507. The decision to implement this stock split reflects the Company’s ai

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.15, which was the closing price of the Company’s common stock on July 6, 2026, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stock Options vesting on the one

3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment ("TME"). The poster is available here. "The data presented at today’s summit shows the advances we have made with the RedTail platform and our progress in addressing a central challenge in immuno-oncology: how to deliver tumor-speci

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into

8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received pre-IND regulatory feedback from the U.S. Food and Drug Administration (FDA) providing alignment and clarity on Calidi's IND-enabling preclinical plans and clinical strategy for CLD-401 prior to advancing the drug candidate into Phase 1 clinical studies. "We thank the FDA for its regulatory feedback, and we believe we are in agreement with the agency on our overall IND strategy for CLD-401," said Calidi Biotherapeutics Chief Executive Officer Eric Poma, Ph.D.

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, will participate in an investor webinar hosted by RedChip Companies ("RedChip") on June 9, 2026, at 1:15pm PT. The exclusive event will feature Eric Poma, Ph.D., Chief Executive Officer of Calidi, who will provide investors with an in-depth overview of Calidi's breakthrough RedTail platform, a next-generation targeted virotherapy designed to deliver genetic medicines systemically to metastatic sites of disease. The discussion will highlight the Company's progress advancing CLD-401, its lead RedT